Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

NASDAQ:MRVI - Nasdaq - US56600D1072 - Common Stock - Currency: USD

2.42  -0.09 (-3.59%)

Fundamental Rating

2

Taking everything into account, MRVI scores 2 out of 10 in our fundamental rating. MRVI was compared to 56 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRVI has reported negative net income.
In the past year MRVI had a positive cash flow from operations.
In multiple years MRVI reported negative net income over the last 5 years.
In the past 5 years MRVI always reported a positive cash flow from operatings.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

MRVI has a Return On Assets (-16.95%) which is in line with its industry peers.
MRVI has a Return On Equity of -54.13%. This is in the lower half of the industry: MRVI underperforms 69.64% of its industry peers.
Industry RankSector Rank
ROA -16.95%
ROE -54.13%
ROIC N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

MRVI has a Gross Margin of 37.29%. This is in the lower half of the industry: MRVI underperforms 60.71% of its industry peers.
In the last couple of years the Gross Margin of MRVI has declined.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRVI has been increased compared to 1 year ago.
The number of shares outstanding for MRVI has been reduced compared to 5 years ago.
MRVI has a better debt/assets ratio than last year.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.09, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
MRVI has a worse Altman-Z score (1.09) than 62.50% of its industry peers.
A Debt/Equity ratio of 1.07 is on the high side and indicates that MRVI has dependencies on debt financing.
MRVI has a worse Debt to Equity ratio (1.07) than 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z 1.09
ROIC/WACCN/A
WACC11.93%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

MRVI has a Current Ratio of 5.96. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
MRVI has a better Current ratio (5.96) than 78.57% of its industry peers.
A Quick Ratio of 5.17 indicates that MRVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.17, MRVI belongs to the top of the industry, outperforming 80.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.96
Quick Ratio 5.17
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for MRVI have decreased strongly by -700.00% in the last year.
The Revenue for MRVI has decreased by -11.77% in the past year. This is quite bad
Measured over the past years, MRVI shows a quite strong growth in Revenue. The Revenue has been growing by 12.61% on average per year.
EPS 1Y (TTM)-700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)-11.77%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-27%

3.2 Future

Based on estimates for the next years, MRVI will show a very negative growth in Earnings Per Share. The EPS will decrease by -27.47% on average per year.
The Revenue is expected to grow by 0.67% on average over the next years.
EPS Next Y-192.4%
EPS Next 2Y-52.22%
EPS Next 3Y-21.61%
EPS Next 5Y-27.47%
Revenue Next Year-25.11%
Revenue Next 2Y-8.86%
Revenue Next 3Y-2.09%
Revenue Next 5Y0.67%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

MRVI's earnings are expected to decrease with -21.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.22%
EPS Next 3Y-21.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (7/18/2025, 3:23:35 PM)

2.42

-0.09 (-3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners75.9%
Inst Owner Change0%
Ins Owners3.39%
Ins Owner Change64.44%
Market Cap616.28M
Analysts76.67
Price Target5.99 (147.52%)
Short Float %12.75%
Short Ratio7.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.43%
Min EPS beat(2)-47.06%
Max EPS beat(2)-9.8%
EPS beat(4)0
Avg EPS beat(4)-77.96%
Min EPS beat(4)-154.98%
Max EPS beat(4)-9.8%
EPS beat(8)2
Avg EPS beat(8)-57.51%
EPS beat(12)5
Avg EPS beat(12)-37.67%
EPS beat(16)9
Avg EPS beat(16)-22.37%
Revenue beat(2)1
Avg Revenue beat(2)0.53%
Min Revenue beat(2)-3.3%
Max Revenue beat(2)4.37%
Revenue beat(4)2
Avg Revenue beat(4)-0.96%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)4.37%
Revenue beat(8)4
Avg Revenue beat(8)-0.66%
Revenue beat(12)5
Avg Revenue beat(12)-1%
Revenue beat(16)8
Avg Revenue beat(16)0.5%
PT rev (1m)7.26%
PT rev (3m)-0.2%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)-12.81%
EPS NY rev (1m)-2.91%
EPS NY rev (3m)-24.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.81%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)1.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.55
P/FCF N/A
P/OCF 94.2
P/B 2.05
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.03
OCFY1.06%
SpS0.95
BVpS1.18
TBVpS-0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.95%
ROE -54.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.29%
FCFM N/A
ROA(3y)-4.24%
ROA(5y)0.56%
ROE(3y)-10.9%
ROE(5y)22.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.26%
GM growth 5Y-4.76%
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.11%
Cap/Sales 12.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.96
Quick Ratio 5.17
Altman-Z 1.09
F-Score5
WACC11.93%
ROIC/WACCN/A
Cap/Depr(3y)80.93%
Cap/Depr(5y)80.31%
Cap/Sales(3y)12.22%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-192.4%
EPS Next 2Y-52.22%
EPS Next 3Y-21.61%
EPS Next 5Y-27.47%
Revenue 1Y (TTM)-11.77%
Revenue growth 3Y-31.3%
Revenue growth 5Y12.61%
Sales Q2Q%-27%
Revenue Next Year-25.11%
Revenue Next 2Y-8.86%
Revenue Next 3Y-2.09%
Revenue Next 5Y0.67%
EBIT growth 1Y-82.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1180.16%
EBIT Next 3Y144.98%
EBIT Next 5Y-46.6%
FCF growth 1Y-105.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-98.57%
OCF growth 3Y-72.74%
OCF growth 5Y-20.9%